Aranesp
(darbepoetin alfa)ApprovedBiologic
AmgenDarbepoetin alfa is used to treat anemia (low red blood cell count) in patients with chronic kidney disease or cancer patients receiving chemotherapy. It works by stimulating the body to produce more red blood cells.[2] Aranesp is currently approved and in use across 29 indications[4].[1]
Aranesp is one of 736 biologic programs targeting Dysgerminoma. It is currently in Approved.
29
Indications
137
Total Trials
6
Active Trials
735
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 28 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Aranesp
AmgenApproved
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Bisphosphonate
AmgenPreclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease40 trials
Show 37 more trials
Anemia38 trials
Show 35 more trials
Non-Small Cell Lung Cancer4 trials
Myelodysplastic Syndrome4 trials
31 more indications
Erythropoietin3 trials
Myeloid Malignancies3 trials
Congestive Heart Failure3 trials
Heart Failure3 trials
Breast Cancer2 trials
MDS2 trials
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT04798339·13 enrolled
Lung Cancer2 trials
Chemotherapy2 trials
Infants2 trials
Diffuse Large B-Cell Lymphoma1 trial
Tics1 trial
Quality of Life1 trial
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
Completed·—·Phase 4·NCT00153868·43 enrolled
Lymphoma1 trial
Complication1 trial
Colorectal Cancer1 trial
The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
Completed·—·Phase 4·NCT00122720·200 enrolled
Germ Cell Tumor1 trial
Prostate Cancer1 trial
Allogeneic Stem Cell Transplantation1 trial
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
Completed·—·N/A·NCT00355407·31 enrolled
Diabetic Nephropathy1 trial
A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy
Terminated·—·N/A·NCT00907608·16 enrolled
Kidney Transplant1 trial
Prophylaxis1 trial
Unspecified5 trials
EPO-4-Rhesus Study
Unknown status·SSanquin-LUMC J.J van Rood Center for Clinical Transfusion Research·Phase 2/3·NCT03104426·42 enrolled
Show 2 more trials
Regulatory
FDA Approval Timeline[5]
Sep 17, 2001
ARANESP
BLA BLA103951
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aranesp drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for darbepoetin alfa. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]